Assessment of risk factor for death in dengue haemorrhagic fever and dengue shock syndrome by Senthil Kumar, K
“ASSESSMENT OF RISK FACTOR FOR DEATH IN DENGUE 
HAEMORRHAGIC FEVER & DENGUE SHOCK SYNDROME”
Dissertation Submitted For
M.D DEGREE EXAMINATION
BRANCH VII – PAEDIATRIC MEDICINE
INSTITUTE OF CHILD HEALTH
AND
HOSPITAL FOR CHILDREN
MADRAS MEDICAL COLLEGE
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY
CHENNAI
MARCH - 2010
CERTIFICATE
This is to certify that the dissertation titled “ASSESSMENT OF RISK FACTOR FOR 
DEATH  IN  DENGUE  HAEMORRHAGIC  FEVER  &  DENGUE  SHOCK 
SYNDROME” submitted  by  Dr.K.Senthil  Kumar to  the  Faculty  of  pediatrics,  The 
Tamilnadu  Dr.  M.G.R.  Medical  university,  Chennai  in  partial  fulfillment  of  the 
requirement for the award of M.D. Degree( Paediatrics) is  a bonafide research work 
carried out by him under our direct supervision and guidance.
Dr.J.MOHANASUNDARAM,
M.D., Ph.D., DNB,
Dean, 
Madras Medical College,
Chennai - 3.
Dr.SARADHA SURESH,
M.D., Ph.D.,F.R.C.P(Glascow)
Director & Superintendent,
   Institute of Child Health and
Hospital for Children, 
       Egmore, Chennai - 8.
            
         
DECLARATION
I.  DR.K.Senthil Kumar solemnly declare that the dissertation titled “ASSESSMENT 
OF RISK FACTOR FOR DEATH IN DENGUE HAEMORRHAGIC FEVER & 
DENGUE SHOCK SYNDROME” has been prepared by me.
This  is  submitted  to  The Tamilnadu Dr.  M.G.R.  Medical  University,  Chennai  in 
partial  fulfillment  of  the  rules  and regulations  for  the  M.D.  Degree  Examination  in 
Paediatrics.
Dr.K.Senthil Kumar
Place :  Chennai
Date :    
ACKNOWLEDGEMENT
At the outset I thank the Lord, Almighty, for giving me the strength to perform all 
my duties.
It  is  indeed a  great  pleasure  to  recall  the  people  who have  helped me in  the 
completion of my dissertation. To name all of them would be impossible, yet I attempt to 
show my gratitude to a select few, who have been indispensable and to whom I am 
greatly indebted.
I  would  like  to  express  my  sincere  gratitude  to  Dr.SARADHA  SURESH,
M.D.,Ph.D.,F.R.C.P(Glascow)  Professor of Paediatrics, Director and Superintendent of 
Institute  guidance,  constant  supervision,  encouragement  and  support  throughout  the 
study.
I owe debt of gratitude to my unit chief  Dr.P.S. Muralidharan MD., DCH
for  his  invaluable  guidance,  constant  supervision,  encouragement  and  support 
throughout the study.
I am extremely thankful  to Dr R.Somasekar MD.,DCH., former assistant professor of 
Paeditrics for his compassionate guidance throughout my study
I would like to thank my unit Assistant Professors of Paeditrics, 
Dr  N.Rathinavelu MD,  Dr  B.Sathyamoorthy MD.,DCH.,  Dr  S.Parivathini 
MD.,DCH.,for their valuable guidance and assistance in doing this work.
I extend my special thanks to Dr P.Jayachandran MD., DCH.,
 Professor of  Paediatrics , Deputy Director of Institute for his critical appreciation and 
help in completing this work.
I  would  like  to  thank  to  Dr.P.Ramachandran MD.,  DCH.,  Professor  of 
Paediatrics for extending support and guidance in doing this work.
I would like to thanks to Dr. K.Nedunchelian MD.,DCH.,                 Assistant 
Professor of Paediatrics for his extreme support and guidance in doing this work.
I sincerely thank all the children and their parents who had submitted themselves 
for this study without whom this study would not have been possible.
ABBREVIATIONS
DF Dengue Fever
DHF Dengue Haemorrhagic Fever
DSS Dengue Shock Syndrome
GI Gastro Intestinal
WHO World Health Organisation
CONTENTS
SL.NO CONTENTS PAGE NO
1. INTRODUCTION 1
2. REVIEW OF LITERATURE 25
3. STUDY JUSTIFICATION 28
4. AIM OF THE STUDY 29
5. SUBJECTS AND METHODS 30
6. OBSERVATION 35
7. DISCUSSION 55
8. SUMMARY AND CONCLUSION 59
9. BIBLIOGRAPHY 60
10. PROFORMA 63
8                                      INTRODUCTION 
Dengue, a Spanish alteration of the Swahili word Ki-dinga, is the most common 
mosquito-born viral illness in humans.  The earliest  known documentation of 
dengue like symptoms was recorded in the Chinese Encyclopaedia of Symptoms 
during  the  Chin  Dynasty  (AD 265-420).  The  illness  was  called  "the  water 
poison" and was associated with flying insects near water.
Reason for  mortality  in DHF/DSS1 Failure to recognise the patient in shock 
,Haemorrhage,  Failure to recognise the patient had entered congestive phase 
may cause cardiac overload  and consequent congestive heart failure and death . 
There  has  been  paucity  of  data  regarding the  usefulness  of  clinical  and lab 
investigation in predicting the death in DHF/DSS.
Hence  this  study  was  carried  out  to  study  the  predictive  value  of  clinical 
parameters and abnormal laboratory values in dengue illness. The present study 
may place in perspective the role of clinical parameter  and laboratory values in 
finding out the risk factor leading to death 
Dengue Epidemiology
Dengue is the most rapidly spreading mosquito-borne viral disease in the world. 
In the last 50 years, incidence has increased 30-fold with increasing geographic 
expansion to  new countries  and,  in  the  present  decade,  from urban to  rural 
setting.  An  estimated  50  million  dengue  infections  occur  annually  and 
9approximately 2.5 billion people live in dengue endemic countries20 .  During 
epidemics of dengue attack rates among susceptible are often 40%-50%, 90% of 
hospitalised DHF were children less than 15years , mortality in dengue is 5%21, 
In India  infections are  becoming more frequent  involvement  of younger age 
group  and  increased  the  frequency  of  epidemics  are  indicator  of  higher 
incidence of infection 2. 
The virus16 
Dengue  virus  (DEN)  is  a  small  single-stranded  RNA virus  comprising  four 
distinct serotypes (DEN-1 to -4).   dengue virus belong to the genus Flavivirus, 
family Flaviviridae. The mature particle of the dengue virus is spherical with a 
diameter of 50nm containing multiple copies of the three structural proteins, a 
host-derived membrane bilayer and a single copy of a positive-sense, single-
stranded RNA genome. The genome is cleaved by host and viral proteases in 
three structural proteins (capsid, C, prM, the precursor of membrane, M, protein 
and envelope, E) and seven nonstructural proteins (NS). 
 The vectors16
The various serotypes of the dengue virus are transmitted to humans through the 
bites of infected Aedes mosquitoes, principally Ae. aegypti. This mosquito is a 
tropical  and subtropical  species widely  distributed around the world,  mostly 
between latitudes 35 0N and 35 0S.  The immature stages are found in water-
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filled  habitats,  mostly  in  artificial  containers  closely  associated  with  human 
dwellings and often indoors. Studies suggest that most female Ae. aegypti may 
spend their lifetime in or around the houses where they emerge as adults. This 
means that people, rather than mosquitoes, rapidly move the virus within and 
between  communities.  The eggs  can remain  viable  for  many  months  in  the 
absence of water
The host16
After an incubation period of 4--10 days, infection by any of the four virus 
serotypes can produce a wide spectrum of illness, although most infections are 
asymptomatic or subclinical .  Primary infection is thought to induce lifelong 
protective immunity to the infecting serotype . Individuals suffering an infection 
are protected from clinical illness with a different serotype within 2--3 months 
of  the  primary  infection  but  with  no  long-term  cross-protective  immunity. 
Individual risk factors determine the severity of disease and include secondary 
infection, age, ethnicity and possibly chronic diseases (bronchial asthma, sickle 
cell anaemia and diabetes mellitus). Young children in particular may be less 
able than adults to compensate for capillary leakage and are consequently at 
greater risk of dengue shock.
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Transmission of the dengue virus16
Humans are the main amplifying host of the virus. Dengue virus circulating in 
the blood of viraemic humans is ingested by female mosquitoes during feeding. 
The  virus  then  infects  the  mosquito  mid-gut  and  subsequently  spreads 
systemically over a period of 8--12 days. After this extrinsic incubation period, 
the  virus  can  be  transmitted  to  other  humans  during subsequent  probing  or 
feeding. The extrinsic incubation period is influenced in part by environmental 
conditions,  especially  ambient  temperature.  Thereafter  the  mosquito  remains 
infective for  the rest of its life.  Ae. aegypti is one of the most efficient vector 
for  arboviruses  because  it  is  highly  anthropophilic,  frequently  bites  several 
times before completing oogenesis, and thrives in close proximity to humans. 
Vertical  transmission  (transovarial  transmission)  of  dengue  virus  has  been 
demonstrated in the laboratory but rarely in the field.
Pathogenesis11
The pathogenesis is incompletely understood, but epidemiologic studies suggest 
that it is usually associated with secondary infections with dengue types 1–4. 
Early in the acute stage of secondary dengue infections, there is rapid activation 
of  the  complement  system.  Shortly  before  or  during  shock,  blood  levels  of 
soluble  tumor  necrosis  factor  receptor,  interferon-γ,  and  interleukin  2  are 
elevated.  C1q,  C3,  C4,  C5–C8,  and C3 proactivators  are  depressed,  and C3 
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catabolic rates are elevated. These factors may interact at the endothelial cell to 
produce increased vascular permeability through the nitric oxide final pathway. 
The blood clotting and fibrinolytic systems are activated, and levels of factor 
XII  (Hageman factor)  are  depressed.  The mechanism of  bleeding in  dengue 
hemorrhagic fever is not known, but a mild degree of disseminated intravascular 
coagulation, liver damage, and thrombocytopenia may operate synergistically11. 
Capillary  damage  allows  fluid,  electrolytes,  small  proteins,  and,  in  some 
instances, red cells to leak into extra vascular spaces. Plasma leakage is thought 
to be associated with functional rather than destructive effects on endothelial 
cells16. Activation of infected monocytes and T cells, the complement system 
and the  production  of  mediators,  monokines,  cytokines  and solublereceptors 
may also be involved in endothelial cell dysfunction This internal redistribution 
of fluid, together with deficits caused by fasting, thirst, and vomiting, results in 
hemoconcentration,  hypovolemia,  increased  cardiac  work,  tissue  hypoxia, 
metabolic  acidosis,  and  hyponatremia. Microscopically,  there  is  perivascular 
edema in the soft tissues and widespread diapedesis of red cells. There may be 
maturational arrest of megakaryocytes in bone marrow, and increased numbers 
of them are seen in capillaries of the lungs, in renal glomeruli, and in sinusoids 
of the liver and spleen.
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Clinical Features:
In  endemic  areas  DHF is  more  commonly  seen  in  children  below 15 
years. The major clinical manifestations seen in typical cases of DHF are high 
fever,  hemorrhagic  phenomena,  hepatomegaly  and  often  circulatory  failure. 
Thrombocytopenia  and hemoconcentation  are  distinctive  laboratory  findings. 
WHO has given guidelines for case definition and grading of DHF.
Case definition of DHF:
        This  is  based on two clinical  criteria  (fever  and bleeding)  and two 
laboratory criteria (low platelet count and vascular leak).
1. Acute onset, high grade, continuous fever for 2-7 days.
2. One of the following hemorrhagic manifestations
A positive tourniquet test
Petechiae, Purpura or ecchymosis
Epistaxis, gum bleeding, GI bleed (hematemesis and / or melena)
3. Evidence of plasma leak:
A rise in hematocrit (Hct) equal to or greater than 20%
Pleural effusion, ascites, or hypoalbuminemia or hypoproteinemia
4. Thrombocytopenia (Platelet count < 1,00,000/ mm3)
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Grades of DHF:
DHF is divided into 4 grades.  The first  two grades are characterized by the 
criteria mentioned above. Grade III and IV are characterised by shock.
Grade  I  DHF:  Criteria  for  DHF  mentioned  above  with  hemorrhagic 
manifestation as positive tourniquet test only
Grade II DHF: Criteria for DHF + skin / mucosal bleeding
Grade III DHF: DHF Criteria with circulatory failure characterized by 
rapid and weak pulse, narrow pulse pressure (20 mm Hg or less) or hypotension 
with cold clammy skin and restlessness.
Grade IV DHF: DHF with profound shock with undetectable pulse and 
blood pressure.
Clinical illness in DHF is characterized by 3 phases (1) Acute febrile phase (2) 
Critical phase and (3) Convalescent Phase. 24
Febrile phase
Patients typically develop   high-grade   fever suddenly. This acute   febrile 
phase  usually lasts 2–7  days and is often accompanied by facial flushing, 
skin erythema, generalized bodyache,   myalgia,  arthralgia  and  headache . 
Some  patients  may  have  sore throat, injected  pharynx and  conjunctival 
injection. Anorexia,  nausea  and  vomiting are common.
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Figure 1. Manifestation of dengue viral infection
     Plasma Leak
Dengue viral infection
Asymptomatic symptomatic
Undifferentiated viral illness Dengue fever Dengue hemorrhagic 
Dengue shock syndrome
DHF III-IV
Non shock
DHF  I - II
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monitoring for warning signs and   other  clinical  parameters   is crucial to 
recognizing  progression to the critical phase.
Mild haemorrhagic  manifestations like petechiae   and  mucosal  membrane 
bleeding (e.g.   nose   and  gums) may be   seen   The liver is often enlarged 
and   tender after a few days of fever . The earliest abnormality in the full 
blood count is a progressive decrease in total white cell count, which should 
alert the physician to a high probability of dengue.
Critical phase
Around the time of defervescence,   when the temperature drops to 37.5–
38oC or less and  remains below  this level, usually on days 3–7  of illness, 
an increase  in  capillary permeability in parallel with increasing haematocrit 
levels may occur . This marks the beginning of the critical phase.  The period 
of clinically significant plasma leakage  usually lasts 24–48 hours.Progressive 
leukopenia followed by a rapid decrease in platelet count usually precedes 
plasma leakage. At this point patients without an increase in  capillary 
permeability will improve, while those with increased  capillary permeability 
may  become  worse as  a result of lost plasma volume. Pleural effusion and 
ascites may be clinically detectable   depending   on the degree   of plasma 
leakage   and the volume of fluid therapy. Hence chest x-ray and abdominal 
ultrasound can be useful tools for diagnosis. The degree  of increase above the 
baseline haematocrit often reflects the severity of plasma leakage.
C
H
A
PTER
 2
17
Shock occurs when  a critical volume of plasma  is lost through leakage. It 
is  often preceded by warning  signs. The body  temperature  may be 
subnormal  when  shock occurs. With prolonged shock, the consequent organ 
hypoperfusion results in progressive organ impairment, metabolic acidosis and 
disseminated intravascular coagulation.  This in turn leads  to severe 
haemorrhage  causing  the  haematocrit  to decrease in severe shock. Instead 
of the leukopenia  usually seen  during this phase  of dengue,  the total white 
cell count may increase in patients with severe bleeding. In addition, severe 
organ impairment such as severe hepatitis, encephalitis or myocarditis and/or 
severe bleeding may also develop without obvious plasma leakage  or shock
Recovery phase
If    the   patient   survives the   24–48 hour   critical phase,    a gradual 
reabsorption  of extravascular compartment fluid takes place  in the following 
48–72 hours. General well-being improves, appetite   returns, gastrointestinal 
symptoms abate, haemodynamic status stabilizes and diuresis ensues. Some 
patients may have a rash of “isles of white in the sea  of red” .  Some may 
experience   generalized   pruritus. Bradycardia   and electrocardiographic 
changes are common during this stage.
The haematocrit stabilizes or may be   lower due to the dilutional effect of 
reabsorbed fluid. White   blood   cell count usually starts to rise soon   after 
defervescence  but the recovery of platelet count is typically later than that of 
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white blood cell count, Respiratory distress from massive pleural effusion and 
ascites will occur at any  time if excessive intravenous fluids have been 
administered. During the critical and/or recovery phases,   excessive fluid 
therapy is associated  with pulmonary  oedema  or congestive heart failure.
Diagnostic Tests in Dengue Infection
There are 3 methods to be looked at
(1) Serology (2) Isolation of virus (3) Demonstration of specific virul antigen or 
viral RNA in serum.
Serology25
Most  widely  used  serologic  test  is  IgM capture  by  ELISA technique 
(MAC – ELISA). It is simple and rapid test. By 6-10 days 93% have detectable 
IgM antibodies, MAC ELISA test requires only a single properly timed blood 
sample after 5 days of fever. Still a negative test does not rule out dengue
Two  types of serologic responses are seen : Primary and secondary. For acute 
and convalescent serum capture IgM (MAC – ELISA) and IgG ELISA are now 
standard  for  detection  and  differentiation  of  primary  and  secondary  DV 
infection.  25  In primary dengue infection, IgM levels an higher. In secondary 
dengue infection IgG levels are higher and IgM is low or absent. Recently by 
capture IgE Elisa, it is shown that DV specific IgE titres are significantly higher 
in DHF and / or DSS patients than in patients with DF. 25
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Viral Isolation
Circulating DV levels early in illness correlate with increasing dengue 
severity. Viral isolation can be done by mosquito inoculation or culture. But it is 
generally not available in many places .
Molecular Diagnosis
Real time one step RNA PCR is the new gold standard for rapid diagnosis 
of dengue infection. 25 It is a simple, rapid method with low contamination rate. 
But the cost is high and is generally not available.
Antigen Detection
DV has  3  structural  protein  genes  and  7  non-structural  protein  (NS) 
genes. Non Structural protein NSI antigen assay by dot blot immue assay in 
serum  and  plasma  samples  of  suspected  DV  infected  patients  is  widely 
evaluated for the diagnosis and prediction of severity of dengue infection.
Principles in Management of DHF and DSS21,24
1. DSS is  a  hypovolemic  shock  due  to  plasma  loss  accompanied  by  an 
increase in peripheral vascular resistance.  The period of short,  but life 
threatening. The Severity of shock is variable.
2. The critical  period of plasma leak with varying degrees of circulatory 
disturbances occurs during the 48 hours around defervescence of fever 
(about 24 hours before and 24 hours after the fall of temperature). The 
critical period may be seen anytime from third day after onset of fever. 
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The vascular leak is limited to a period of about 48 hours after which the 
leaked fluid will be reabsorbed into vascular space. If fluids are given 
inappropriately  or  for  longer  duration  than  necessary,  serious  volume 
overload  and  pulmonary  oedema  can  occur.  Balancing  fluid 
administration  to  prevent  shock  with  avoidance  of  excessive 
administration reqires intensive skilled monitoring.
3. During the critical  period, the child can go in and out of shock many 
times  necessitating  close  monitoring  and  adjustment  of  fluid 
administration.
In  a  child  with fever following  warning  signs  are  explained to 
parents to bring the child immediately to the hospital
Child appears ill, irritable or lethargic as fever subsides
Vomiting and abdominal pain
Very thirsty or refusal to eat / drink
Sweating
Cold extremities
Decreased urine output
Skin bleeds in the form of petechiae or purpura or any bleeding.
Indications for admission
Child is very weak , cannot eat / drink
Any bleeding other than petechiae
21
Platelet count less than 10,0000 /and or increase in Hct 10-20% or 
         pleural effusion or ascites.
Other clinical features of shock / impending shock
Infants
Underlying disease condition. E.g. Heart disease
Parental concern / difficult to follow up
Management of DSS
Only about  1/3  of  patients  with  DHF develop shock.  They  should  be 
managed  in  an  intensive  or  semi  intensive  care  unit  which  should  also  be 
mosquito free.
Judicious volume replacement is necessary in DSS. Shock is a medical 
emergency necessitating prompt and immediate replacement with fluids. Good 
supportive care, frequent monitoring and adjustment of fluid administration are 
the  keys  to  successful  outcome.  Airway  and  respiration  are  maintained  and 
oxygen is administered at highest concentration possible, usually through a non- 
rebreathing mask.
Types of IV fluids and blood products used
Normal saline (NS) or Ringer’s lactate (RL) for initial resuscitation of 
shock; 5% dextrose in RL, NS or ½ NS after correction of shock.
Hyperoncotic  colloids  such  as  dextran  –  40/70  or  6% Hydroxy  ethyl 
starch (hetastarch) or gelatin in refractory shock.
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Fresh whole blood or packed RBC’s – for significant bleed.
FFP – in DIC
Platelets – only in certain specific situations.
For  initial  resuscitation  of  shock  which  may  require  repeated  boluses 
isotonic  crystalloids  (NS or  RL)  are  preferred.  Only  after  shock  correction, 
dextrose containing solutions are used. Frequent monitoring of vital signs and 
urine output with Hct if available, will guide in step up or step down of IV 
fluids.
Monitoring
Pulse,  BP,  capillary  refill  time  (CRT),  consciousness  and  respiration 
should  be  monitored  every  30-60  minutes  or  more  frequently  if  necessary 
during the first 1 to 2 hours and then less frequently after the child is stabilized.
Urine  output  has  to  be  chartered  hourly  with  an  indwelling  urinary 
catheter.
Micro Hct, if available, should be checked initially 1-2 hourly and later 
less frequently as child improves. This is a good indicator of plasma leak and 
reliable guide for further fluids.
Other lab tests such as blood grouping and cross matching; blood sugar, 
blood  gases,  serum  electrolytes  and  calcium,  renal  function  tests  and 
coagulogram (PT, PTT) are done as per clinical situation.
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Fluid Therapy
In grade I – II DHF 5% dextrose in NS or RL in the form of maintenance 
fluid plus fluid deficit of 5-8% is needed initially. This works out to 6ml/kg/hr. 
This is gradually stepped down and stopped in 12-24 hours. 
In Grade III DHF, NS or RL can be administered at 10-20 ml/kg/ over 1 
hour (WHO recommends 5% GNS or 5% dextrose in RL 10ml/kg over 1 hour). 
This  bolus  an  be  repeated.  If  clinical  signs  of  shock  improve  rate  of  fluid 
administration is stepped down gradually. If shock worsens, treatment is given 
as for grade IV DHF.
In grade IV DHF (pulse and BP not  recordable),  20ml  /kg of  NS or  RL is 
infused  rapidly  till  pulses  appear  and  repeated  if  necessary.  As  the  child 
improves, rate of fluid administration is stepped down with periodic monitoring. 
This protocol is based on resuscitation of shock as per PALS guidelines and also 
many recent studies that have tried various fluid options.
If shock persists colloids such as dextran-40 or hetastarch or gelatin at a 
rate  of  10ml/kg/hour  is  administered.  Hct  estimation  is  helpful  in  further 
management.  If  Hct  is  still  high  and  shock  persists,  repeat  colloids  at 
10ml/kg/hour upto 30ml/kg. If Hct is falling and the child is in shock, concealed 
hemorrhage is suspected and fresh whole blood 10ml/kg or 
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Figure 2.Volume replacement flow chart for patients with DHF grade 1 and 2
Initial iv fluid 6ml/kg/hr 5% dextrose in NS or RL for 1 hour
Improvement
improvement
Iv fluid by 5% dextrose in NS 
or  RL successively reducing 
from 6 to 3ml/kg/hr
Further improvement
Discontinue iv after 24 hrs
No improvement
Increase iv 10ml/kg/hr for 2 
hrs
No improvement 
Unstable vital 
signs
improvement
Reduce iv to 6ml/kg/hr with 
further reduction to 3ml/kg/hr 
discontinue after 24 hrs HCT HCT ↑
Blood transfusion 
10ml/kg/hr
Iv colloid (40) 10ml/kg/hr for 1hour
Iv  fluids by successively reducing the flow from 10 
to 6 and 6 to 3 ml/kg/hr discontinue after 24 hrs
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Figure 3.Volume replacement flow chart for patients with DHF 3 & 4
Stabilize airway, breathing ,administer oxygen
HCT↑
improvement
Iv therapy by crystalloids 
successively reducing from 20 to 
10, 10 to 6, 6 to 3 ml/kg/hr
Discontinue iv after 24 to 48 hrs
Further improvement
Immediate rapid volume replacement : initial iv therapy 10-20ml/kg/hr crystalloid 
solution (RL or NS) in DHF grade 3 (maximum 2 boluses) &  20ml/kg till pulse 
appears in DHF grade 4
No improvement
HCT ↓
Blood transfusion
(10ml/kg) 
Iv colloid dextran 40 or plasma 
or starch 10ml/kg/hr repeat if 
necessary
No improvementimprovement
Look for blood loss, acidosis, cardiac 
dysfunction treat accordingly
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packed  RBC’s  5ml/kg  is  infused  (Fig.3).  Transfusions  can  be  repeated  as 
necessary. Volume and type of fluids are to be charted on ½ - 1 hourly basis till  
shock is corrected.
 crystalloid  infusion  is  adequate  for  early  resuscitation.  In  DHF  IV 
(severe shock) colloid may be preferred.
If child improves clinically and has good urine output IV fluid rate is 
gradually  decreased  and  stopped  over  a  period  of  24  hours.  IV  fluid 
administration should be discontinued when Hct decreases to stable  level  of 
40% and child’s appetite returns and urine out put is sufficient. In general fluid 
therapy is not required after 48 hours of treatment of shock. It is very important 
to recognize the improvement in child’s status and appropriately reduce / stop 
IV fluids as there is also restoration of extraverted fluid in convalescent stage.
Most patient of DHF/DSS without severe bleed have good prognosis. A 
serious  pitfall  in  severe  shock  is  failure  to  recognize  concealed  internal 
hemorrhage  and  continued  transfusion  of  colloid  instead  of  blood  /  packed 
RBC’s. This may lead on to volume overload and respiratory failure with high 
mortality. Major clinical challenge in DHF is management of DHF/DSS with 
prolonged shock often complicated by massive bleeding.
Children who do not improve with above measures and are in refractory 
shock are likely to have severe metabolic  problems,  pulmonary oedema and 
DIC.  They  need  escalated  therapy  in  the  form of  invasive  monitoring  like 
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central  venous  pressure  (CVP),  inotropes  and  ventilatory  support  Based  on 
CVP, fluids, blood components and inotropes are infused. A recent study had 
used bedside ECHO cardiogram to assess volume status and cardiac function 
(systolic and diastolic dysfunction) for administration of fluids, inotropes and 
vaso-active agents in refractory cases and careful fluid removal by controlled 
diuresis or dialysis in the event of extensive oedema with better results. 
Indication for colloids
Colloids are indicated in patients who continue to be in shock with high 
Hct  despite  receiving adequate  volume of crystalloid and patients  who have 
signs of fluid overload eg. Respiratory distress from massive pleural effusion 
and  /  or  very  tense  abdomen  It  is  preferable  to  use  colloids  which  are 
hyperoncotic  such  as  dextran-40,  hydroxyethyl  starch  or  gelatin  (Hemaccel) 
than  plasma  as  they  are  more  efficient,  cost  effective  and  blood  related 
complications do not occur.  Maximum dosage of  colloids used is  30 ml/kg. 
Colloids many interfere with hemostais and higher doses may cause transient 
elevation of urea, creatinine or cause acute renal failure.
Indications for blood transfusion
• In patients with severe bleeding such as GI bleeding.
• In patients who have persistent shock after receiving adequate crystalloid 
with decreasing Hct when internal bleeding is suspected.
• Concealed internal bleeding with prolonged shock.
28
Fresh  whole  blood  10ml/kg  or  packed  RBCs  5ml/kg  is  administrated. 
Additional transfusions may be required based on Hct and clinical signs.
Indications  for  platelets In  DHF,  bleeding  may  be  due  to  vascular 
involvement,  thrombocytopenia,  platelet  functional  abnormality  and  /  or 
coagulaopathy. Platelets are administered..
• If there is major bleeding.
• When  platelet  counts  is  less  than  50000/cmm  and  if  any  invasive 
procedure is planned
• In absence of bleeding when platelet count is less than 10000/cmm.
I unit platelet concentrate / 10 kg body weight will raise platelet count by 
about 10000 platelets should be infused rapidly in about 10 minutes. This may 
lead onto volume overload when many units are given.
When DIC is present FFP, platelet concentrate and cryoprecipitate may be 
required.
In DSS about 60% require crystalloid, 20% need colloid and about 15% 
blood components. Only 0.4% require platelets.
Complications of DSS
1. Electrolyte  disturbances  and  metabolic  problems  (hyponatremia, 
hypocalcemia,  hypoglycemia,  acidosis)  are  to  be  identified  and 
corrected.
2. DIC may occur after prolonged shock and uncorrected academia and 
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may cause massive bleed and lethal shock. Monitor PT, PTT and fibrin 
dehydration productions (FDPs) to identify DIC during shock.
3. Fluid overload can occur both during critical and convalescent phases. 
This  is  serious  complication  as  it  may  lead  onto  acute  pulmonary 
oedema,  congestive  heart  failure,  later  respiratory  failure  and  death. 
Administration of correct type of IV fluids in just adequate amounts to 
maintain effective circulation based on frequent monitoring particularly 
hourly urine output will prevent this complication.
Treatment of fluid overload will involve close monitoring of vitals and 
urine  output,  ventilatory  support  if  needed,  CVP  monitoring, 
administration of colloid such as dextran-40 and careful administration of 
IV frusemide, preferably by infusion upto 0.4 mg/kg/hr.
4. Noscocomial  infection such as gram negative sepsis,  pneumonia and 
urinary  tract  infection.  Children  who  have  profound  shock 
(unrecordable BP), massive GI bleed and shock with delayed admission 
may have mortality more than 50%.
Certain unusual manifestations of DHF are increasingly reported 
in recent years
1. Encephalopathy: This  occurs more commonly in infants.  It  may occur 
due to prolonged shock, intracranial bleed, acute hepatic encephalopathy, 
electrolyte imbalance, vascular occlusion and rarely due to dengue virus 
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causing encephalitis.  Seizures, altered sensoirum, spasticity and paresis 
may result.
2. Acute hepatic failure
3. Myocarditis:  Global  hypokinesia  and  decreased  ejection  fraction  may 
result. Arrhythmias, heart blocks, and bradycardia may occur.
Mortality in DHF/DSS is due to 
1. Prolonged shock
2. Fluid overload
3. Massive bleeding which is secondary to prolonged shock and acidosis 
leading on to DIVC
4. Acute hepatic failure and encephalopathy
Mortality  rates  reported  are  from  <1%  to  5%  for  DHF  in  centres 
experienced in  resuscitation.  Mortality  reports  from Indian literature  suggest 
case fatality rate of 26-47%.
DIFFERENTIAL DIAGNOSIS 11
The  differential  diagnosis  of  dengue  fever  includes  viral  respiratory  and 
influenza-like diseases,  the early stages of  malaria,  mild yellow fever,  scrub 
typhus, viral hepatitis, and leptospirosis. Four arboviral diseases have dengue-
like courses but without rash: Colorado tick fever,  sandfly fever,  Rift  Valley 
fever, and Ross River fever
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Prevention11
Several types of dengue type 1–4 vaccines are under development, . Prophylaxis 
consists  of  avoiding  mosquito  bites by  use  of  insecticides,  repellents,  body 
covering  with  clothing,  screening  of  houses,  and  destruction  of  A.  aegypti 
breeding sites. If water storage is mandatory, a tight-fitting lid or a thin layer of 
oil may prevent egg laying or hatching. A larvicide, such as Abate [O,O′-(thiodi-
p-phenylene) O,O,O,O′-tetramethyl phosphorothioate], available as a 1% sand-
granule formation and effective at  a concentration of  1  ppm, may be added 
safely  to  drinking  water.  Ultra-low-volume  spray  equipment  effectively 
dispenses the adulticide malathion from truck or airplane for rapid intervention 
during an epidemic. Only personal antimosquito measures are effective against 
mosquitoes in the field, forest, or jungle.
The possibility exists that dengue vaccination may sensitize a recipient so that 
ensuing dengue infection could result in hemorrhagic fever. Vaccination with 
yellow fever 17D strain has no effect on the severity of dengue illness, although 
seroconversion  rates  to  a  dengue  type  2  vaccine  were  enhanced  in  persons 
immune to yellow fever.
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Review  Of Literature  
1.  Vinod H rategeri et al. 5 department of paediatrics, Karnataka institute of 
medical sciences, hubli .  done a study, in 23 children on clinical profile 
and outcome of dengue treatment  .  35% were infants ,  severity more 
noticed in females , common clinical features noted in order of frequency 
were fever (100%), vomiting (82%) , abdominal pain (67%), restlessness 
65% , headache 22%.
2. Kalyanarooj et al6 queen sirikit national institute of child health Bangkok. 
studied on 4532 cases observed that malnourished children had a higher 
risk of developing shock and high case fatality rate .
3. Batra prerna et al10 department of paediatrics, mahatma Gandhi institute 
of medical sciences sevagram maharastra . studied 499 patients and found 
that  children  who  were  referred  late,  had  profound  shock  and 
unconsciousness , were expired within 24hours of admission. 
4. Banik et al12  department of paediatrics and virology medical college and 
school  of  tropical  medicine  Calcutta,  conducted  study on 72 children. 
causes of death included bleeding 47%, shock 35%, both 18%. In more 
severe disease abdominal pain , hepatomegaly and ascitis were usually 
associated .
5. Eric .C.M van grop et al 7. Conducted a study on 50 children, found that 
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total cholesterol were decreased in patients with severe disease.
6. Sivabalan et al chennai8. Conducted a study on 60 children and fond that 
raised ALT, tender hepatomegaly abdominal pain , abdominal distension 
and respiratory distress were significant predictors of bleeding.
7. Anuradha  et  al14 .  conducted  a  study  in  dengue,  found  that  bleeding 
manifestation in DSS was associated with higher mortality.
8. Chua mn et al9  conducted a study in dengue and found that patients with 
a platelet count of <50,000 had a six fold increase in mortality. 
9. Bridget et al from oxford university clinical research unit  13  conducted 
study on 383 children   and found ringer  lactate  to  be more  useful  in 
moderately severe shock, colloid (starch) to be little more advantage in 
severe shock. Use of dextran was  questioned because of its side effects. 
10. Ranjit,el  al17 .conducted  study  on DSS ,   Patients  with  dengue shock 
syndrome  are  at  high  risk  of  mortality  due  to  refractory  shock  and 
multiple organ failure.  Aggressive shock management and possibly the 
use  of  judicious  fluid  removal  may  decrease  mortality  rates  in  the 
severest forms of dengue shock syndrome.
11. N. M. Dung et al18  conducted study on Fluid Replacement in Dengue 
Shock  Syndrome:  A Randomized,  Double‐Blind  Comparison  of  Four 
Intravenous‐Fluid  Regimens. Dextran  70  provided  the  most  rapid 
normalization  of  the  hematocrit  and  restoration  of  the  cardiac  index, 
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without  adverse  effects,  and  may  be  the  preferred  solution  for  acute 
resuscitation in DSS.
12. Shrishu R. Et al19 . Conducted study on Clinical features, complications 
and  atypical  manifestations  of  children  with  severe  forms  of  dengue 
hemorrhagic fever in South India it was found that complications such as 
DIC,  diastolic  dysfunction,  abdominal  compartment  syndrome,  ARDS 
and hepatic dysfunction were more frequent in severe established shock. 
Children  referred  late  were  harder  to  resuscitate.  There  were  9  PICU 
deaths (case fatality rate of 8.35%). Severe refractory shock, DIC, ARDS, 
hepatic failure and neurological manifestations singly or in combination 
were the commonest causes of death.
13. K. Yusoff, et al 23  National University of Malaysia and Lumpur, Malaysia 
Abnormal  ECG seen in 15 patients  (65%) consisted  of.   Abnormal 
echocardiograms   were  present   in  12  patients   (52%);  these   were 
pericardial  effusion,  abnormal   systolic   and diastolic  functions,   left 
ventricular   dilatation,   and  tricuspid   regurgitation  ECG  and 
echocardiographic  abnormalities  are common  during  the acute  phase 
of dengue  haemorrhagic  fever. Cardiac involvement  in the pathogenesis 
of the more severe  forms of dengue  remains  to be defined .
Study justification 
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Untreated  cases  of  DHF  &  DSS  carry  a  mortality  of  20%  (3),  but  early 
recognition and management dramatically reduces the mortality to less than 1 % 
Dengue,   an  arboviral  infection  ,  which  occur  in  epidemics,  should  be 
continuously evaluated for any change in current situation . There is no study 
available from our institute for the assessment of risk factors for death in DHF 
& DSS 
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Aim of the study
To assess the risk factor for death in DHF & DSS among children admitted in 
tertiary referral hospital 
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Subjects and methods
Study design   : nested case control 
                               Case - children who were diagnosed as DHF & 
                                          DSS and expired
                               Control - children who were diagnosed as DHF 
                                             & DSS and discharged well
Study place     : institute of child health and hospital for  
                                children  Egmore Chennai
Period of study: October 2007 to September 2009
Study population: children less than 12 years 
Inclusion criteria:
All Children who satisfy WHO criteria for DHF & DSS11
Fever 
Minor or major hemorrhagic manifestation 
Thrombocytopenia (platelet < 1,00,000/mm3)
Objective evidence of increased capillary permeability 
(HCT >20% of initial level, pleural effusion in chest x ray, hypoalbuminemia)
Exclusion criteria:
Co infection of dengue with leptospirosis, typhoid, malaria, etc
Children treated outside hospital with IV fluids or inotropes 
Children who went against medical advice .
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Sample size:
Total number of DHF & DSS cases during study period 
Percentage of least expected prevalent risk factor in case and control = 1:3 
Manoeuvre 
After getting informed consent, clinical data are collected and entered in the 
proforma (annexure 1) which includes details about the case history, clinical 
findings,  lab  investigations  .  these  patients  are  divided  in  to  two groups  ie 
patients  who were  expired and patients who were discharged well
The clinical and lab data of DHF & DSS patients are analysed and compared 
between these two groups. Various clinical and lab parameters are analysed to 
assess their value as risk factors for death. 
The following parameters are compared between two groups 
Age: since the reported mortality rate in previous studies is higher in < 1 year, 
so infants are compared with older children for mortality risk
Sex: severity   of disease is more noticed in female , so it is analysed to assess 
whether gender is a risk factor for death 
Nutrition Status: severe under nutrition  is associated with higher risk for death 
and hence analysed for risk of death 
Time from onset of fever to presentation to hospital:
more than 5 days is compared with less than 5 days for risk of death 
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Clinical status at presentation 
Shock in DHF & DSS  is  associated with high mortality  ,  so presence and 
absence of shock is assessed for risk factor for death, in shock fluid refractory is 
associated with high mortality so fluid refractory shock with fluid responsive 
shock is assessed for risk factor for death
Hematocrit 
Hematocrit > 37.5 is associated with risk of bleeding and death , so its risk 
factor for death is assessed with hematocrit < 37.5
Platelets
Platelets< 50000 is associated with 6times increase in mortality, so platelets 
<50000 is compared with platelets >50000 for risk factor for death
ALT
More than 3 times normal is associate with high risk for bleeding and death , so 
its risk for death is analysed with ALT less than 3 times normal
Total cholesterol
Value less than 90.8 mg is associated is risk of death. So its risk for death is 
analysed with cholesterol value more than 90.8
Colloids
Colloids not given to the sever  DSS has high mortality , so  it is assessed for 
risk factor for death 
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Blood products ( FFP/ prbc) 
It is analysed to assess weather not giving blood product in appropriate time is 
associated with mortality
Inotropes 
It is analysed to assess weather not giving inotropes in appropriate time is 
associated with mortality
Risk Factors Analysing in DHF/DSS for death
1. Age
2. Sex
3. Nutritional status
4. Time of presentation to hospital
5. Clinical state at presentation - shock
6. Fluid refractory shock
7. Hematocrit > 37.5
8. Platelet <50,000
9. ALT > 3 times normal
   10.Total cholesterol < 90.8 mg
    11.Colloid 
    12. Blood products
    13. ionotropes
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Statistical analysis
Data was entered in Microsoft office excel and analyzed using SSPS ver.11.0 
for windows 
Descriptive statistics like frequencies and percentage were obtained for 
categorical variables association between categorical variables were determined 
using chi-square test 
Univariate ordinal regression with death as the outcome variable was done . this 
provided an odds ratio for each of the risk factor for death. In order to determine 
how the significant risk factors  are acting independently a multiple ordinal 
regression model was developed . variables that were significant in chi-square 
test and those that had a theoretical importance were included in the model 
For  all the above statistical procedures , significance was determined at 5%
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0BSERVATIONS
Total cases studied : 125
No of cases expired : 30
No of case recovered : 95
Table- 1
In this study mortality in DSS  is 42%, DHF is 7% overall mortality out of 125 
cases studied is 24% , in this study death death occur on an average time of 48 
hrs after hospitalisation ( with maximum of 10 days to minimum of 6 hrs after 
hospitalisation )
Total number of cases in DHF & DSS
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<1y expired; 9
<1y survived; 24
>1y expired; 21
>1y survived; 71Table-2 .Age and sex
variables
Expired
 N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR 95%
    C.I
P Value
Age
<1 yr 9(30%) 24(25.3%) 33(26.4%)
1.268 0.15,3.1 0.608
  
>1 yr
    
   21(70%)    71(74.7%)  97(73.6%)
Sex
Female 19(63.3%) 45(47.7%) 64(51.2%)
1.917 0.82,4.4 0.127
Male 11(36.7%) 50(52.6%) 61(48.8%)
In this study below 1 year constitute 26.4 % and 73.6% constitute
above 1 year. Odds of children expired less than 1 year is 1.26 when compared 
to  those  recovered  which  is  not  statistically  significant  OR(95%  CI)  = 
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1.26(0.6,2.8). Odds of children expired having female gender is 1.9 , when 
compared to those who recovered which is not statistically significant OR(95% 
CI) = 1.9( 0.82,4.4) 
Table 3 Nutritional status and Fever in DSS &  DHF
variables
Expired
 N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR
  
   95%
C.I
   
   P 
Value
Nutritiona
l
status
G3/ G4 4(13.3%) 20(82.1%) 24(19.2%)
0.57 0.18,1.8 0.349
N/G1/G2 26(86.7%) 75(17.9%) 101(80.8%)
Fever
>5 days 19(63.3%) 31(32.6%) 50(40%)
3.6 1.5,8.4 0.003
<5 days 11(36.7%) 64(67.4%) 75(60%)
Odds of children expired in severely malnourished  is 0.57 when compared to 
those recovered which is not statistically significant OR(95% CI) = 0.57(0.8,1.8) 
Odds of children expired with fever more than 5 days is 3.6 when compared to 
those recovered which is statistically significant OR(95% CI) = 3.56(1.5, 8.4) 
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Table 4 Symptom analysis in DSS & DHF
variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR   95%
C.I
P Value
Abdomen
Pain
present 8(26.7%) 23(24.2%) 31(24.8%)
1.13 0.4,2.9 0.786
absent 22(73.3%) 72(75.8%) 94(75.2%)
Abdomen
distension
present 6 (20%) 14(14.7%) 20(16%)
1.44 0.5,4.1 0.493
absent 24(80%) 81(85.3%) 105(84%)
Vomiting present 11(36.7%) 44(46.3%) 55(44%)
0.67 0.2,1.5 0.353
absent 19(63.3%) 51(53.7%) 70(56%)
Diarrhoea present 5(16.7%) 12(12.6%) 17(13.6%)
1.38 0.4,4.3 0.574
absent 25(83.3%) 83(87.4%) 108(86.4%)
47
Symptom analysis in DSS & DHF
Skin bleeds present 8(26.7%) 12(12.6%) 20(16%)
2.51 0.9,6.9 0.068
absent 22(73.3%) 83(87.4%) 105(84%)
Mucosal
bleeds
present 2(6.7%) 3(3.2%) 5(4%)
2.19 0.3,13.7 0.393
absent 28(93.7%) 92(96.8%) 120(96%)
G.I bleeds present 12(40%) 24(25.3%) 36(28.8%)
1.97 0.8,4.6 0.120
absent 18(60%) 71(74.4%) 89(71.2%)
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Symptom analysis in DSS & DHF
variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N =125
n (%)
OR 95%
  C.I
P Value
Convulsions present 16(53.3%) 25(26.3%) 41(32.8%)
3.2 1.3,7.4 0.006
absent 14(46.7%) 70(73.7%) 84(6.2%)
Breathlessnes present 15(50%) 17(17.9%) 32(25.6%)
4.5 1.8,11.1 0.000
absent 15(50%) 78(82.1%) 93(74.4%)
Oedema present 10(33.3%) 19(20%) 29(23.2%)
2.0 0.8,4.9 0.131
absent 20(66.7%) 76(80%) 96(76.8%)
Lethargy present 24(80%) 52(54.7%) 76(60.8%)
3.3 1.2,8.8 0.013
absent 6(20%) 43(45.3%) 49(39.2%)
• In patients expired most common symptom other than fever is lethargy 
80%, second most common symptom is convulsion 53.3%, least common 
symptom is mucosal bleed 6.7%
• In patients recovered most common symptom other than fever is lethargy 
54.4%, second most common symptom is vomiting 46.3%, least common 
symptom is mucosal bleed 3.2%
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• Odds of children expired having abdomen pain  is 1.1 when compared to 
those  recovered  which  is  not  statistically  significant  OR(95%  CI)  = 
1.1(0.4, 2.9) 
• Odds  of  children  expired  having  abdomen  distension  is  1.4  when 
compared  to  those  recovered  which  is  not  statistically  significant 
OR(95% CI) = 1.4(0.5, 4.1) 
• Odds  of  children  expired  having  vomiting  is  0.67  when  compared  to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
0.67(0.2, 1.5) 
• Odds of children expired having diarrhoea   is  1.3 when compared to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
1.3(0.4, 4.2) 
• Odds of  children  expired  having skin  bleed is  2.5  when compared to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
2.5(0.9, 6.9) 
• Odds of children expired having mucosal bleed is 2.1 when compared to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
2.1(0.3, 13.7) 
• Odds  of  children  expired  having  gastrointestinal  bleed  is  1.9  when 
compared  to  those  recovered  which  is  not  statistically  significant  OR 
(95% CI) = 1.9(0.8, 4.6) 
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• Odds of children expired having convulsions is 3.2 when compared to 
those recovered which is statistically significant OR (95% CI) = 3.2(1.3, 
7.4) 
• Odds of children expired having breathlessness is 3.2 when compared to 
those recovered which is statistically significant OR (95% CI) = 3.2(1.8, 
11.1) 
• Odds of children expired having oedema is 2 when compared to those 
recovered which is not statistically significant OR (95% CI) = 2(0.8, 4.9) 
• Odds of children expired having lethargy is 3.3 when compared to those 
recovered which is statistically significant OR (95% CI) = 3.3(1.2, 8.0) 
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Table 5 Shock in DSS & DHF
variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR 95%
C.I
    P 
Value
Peripheral
temperature
Cold 26(86.7%) 41(43.2%) 67(53.6%)
8.5 2.7,26.4 0.000
Warm 4(13.3%) 54(56.8%) 58(46.4%)
Peripheral
Pulse
Not felt 19(63.3%) 18(18.9%) 37(29.6%)
7.3 2.9,18.2 0.000
Felt 11(36.7%) 77(81.1%) 88(70.4%)
shock Present 27(90%) 47(49.5%) 74(59.2%)
9.1 2.6,32.3 0.000
absent 3(10%) 48(50.5%) 51(40.8%)
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variables
Expired 
N = 27
n (%)
Recovered
N = 47
n (%)
Total
N = 74
n (%)
OR  95%
   C.I
P Value
If
Shock
present
Fluid
refractory 25 31 56
6.45 3.05,13.
3
0.02
Fluid
responsive 2 16 18
• Odds of children expired having cold periphery is 8.5 when compared to 
those recovered which is statistically significant OR (95% CI) = 8.5(2.7, 
26.4) 
• Odds  of  children  expired  having  absent  peripheral  pulse  is  7.3  when 
compared to those recovered which is statistically significant OR (95% 
CI) = 7.3(2.9, 18.2) 
• Odds of children expired having shock is 9.1 when compared to those 
recovered which is statistically significant OR (95% CI) = 9.1(26, 32.3) 
• Odds  of  children  expired  having  fluid  refractory  shock  is  6.4  when 
compared to those recovered which is statistically significant OR (95% 
CI) = 6.4(3.0, 13.3) 
Table  6 Clinical sign in DSS & DHF
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variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR   95%
C.I
P Value
Hepatomegaly
Present 29(96.7%) 90(94.7%) 119(95.2%)
1.6 0.18,14.3 0.666
Absent 1(3.3%) 5(5.3%) 6(4.8%)
splenomegaly
Present 6(20%) 15(15.8%) 21(16.8%)
1.3 0.46,3.8 0.591
Absent 24(80%) 80(84.2%) 104(83.2%)
unconsciousness
Present 24(80%) 47(49.5%) 71(56.8%)
4.0 1.5,10.8 0.03
Absent 6(20%) 48(50.5%) 54(43.2%)
• Odds of children expired having hepatomegaly  is 1.6 when compared to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
1.6(0.18, 14.3) 
• Odds of children expired having spleenomegaly  is 1.3 when compared to 
those  recovered  which  is  not  statistically  significant  OR (95% CI)  = 
1.3(0.4, 3.8) 
• Odds of children expired having unconscious is 4.8 when compared to 
those recovered which is statistically significant OR (95% CI) = 4.8(1.5, 
10.8) 
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Table 7 Hematocrit and platelets in DSS & DHF
variables
Expired
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR
 
  95%
C.I
P 
Value
Hematocri
t
> 37.5 11(36.7%
)
51(53.7%) 62(49.6%)
0.4 0.21,1.1 0.104
< 37.5 19(63.3%
)
44(46.3%) 63(50.4%)
Platelets
< 50,000 26(86.7%
)
78(82.1%) 104(83.2%
) 1.4 0.43,4.5 0.560
> 50,000 4(13.3%) 17(17.9%) 21(16.8%)
• Odds of children expired having hematocrit more than 37.5 is 0.4  when 
compared to those recovered which is not statistically significant 
OR(95% CI) = 0.49(0.21, 1.1) 
• Odds of children expired having platelets less than 50,000 is 1.4 when 
compared to those recovered which is not statistically significant 
OR(95% CI) = 1.4(0.4, 4.5) 
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Table 8 ALT ,cholesterol in DSS & DHF
variables
Expired
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR   95%
C.I
P 
Value
ALT
> 3times 23(76.7%) 52(54.7%) 75(60%)
2.7 1.0,6.9 0.03
< 3 
times
7(23.3%) 43(45.3%) 50(40%)
cholesterol
< 90.8 6(20%) 0(0%) 6(4.8%)
0.00
> 90.8 24(80%) 95(100%) 119(95.2%)
• Odds of children expired having ALT more than 3 times is 2.7 when 
compared to those recovered which is statistically significant OR (95% 
CI) = 2.7(1.0, 6.9) 
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Table 9 Radiology in DSS & DHF
variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR   95%
C.I
P Value
Chest
X ray
cardiomegal
y
14(46.7
%)
    
    3(3.2%) 17(13.6%)
26.8 6.9,104 0.000
No
cardiomegal
y
16(53.3
%) 92(96.8%) 108(86.4
%)
USG
Ascitis 18(60%) 73(76.8%) 91(72.8%)
0.15 0.18,1.0
8
0.071
No ascitis 12(40%) 22(23.2%) 34(27.2%)
• Odds of children expired having cardiomegaly is 26.8  when compared to 
those recovered which is  statistically significant OR(95% CI) = 26.8(6,9, 
104) 
• Odds of children expired having ascitis is 0.15  when compared to those 
recovered which is not statistically significant OR(95% CI) = 0.15(0.18, 
1.08) 
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Table 10 Treatment in DHF & DSS
variables
Expired 
N = 30
n (%)
Recovered
N = 95
n (%)
Total
N = 125
n (%)
OR   95%
C.I
P Value
Colloids
given
14(46.7%) 13(13.7%) 27(21.6%)
2.6 2.6,11.2 0.03
Not 
Given 16(53.3%) 82(86.3%) 98(78.4%)
Ffp / prbc
given
12(40%) 18(18.9%) 30(24%)
2.85 1.4,5.6 0.02
Not 
Given 18(60%)    77(81.1%) 95(76%)
Initial
ionotropes
given
24(80%) 31(32.6%) 55(44%)
8.2 4.6,16.2 0.01
Not 
given 6(20%) 64(67.4%) 70(56%)
 Odds of children expired received colloids is 5.5  when compared to 
those recovered which is   statistically significant OR (95% CI) = 5.5(2.6, 
11.2) 
 Odds of children expired received FFP/PRBC is 2.85 when compared to 
those recovered which is statistically significant OR (95% CI) = 
2.85(1.4,5.6) 
 Odds of children expired received ionotropes is 8.2 when compared to 
those recovered which is  statistically significant OR(95% CI) = 8.2(4.6, 
16.2) 
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Table  11  Risk factor for death  in  DHF & DSS derived  by  univariate 
logistic regression analysis
variable OR 95% CI p- value
fever > 5 days 3.5 1.5, 8.4 0.003
< 5 days
convulsion Present 3.2 1.3, 7.4 0.006
Absent 
breathlessness Present 4.5 1.8,11.1 0.000
Absent 
lethargy Present 3.3 1.2, 8.8 0.013
Absent 
Shock Present 9.1 2.6, 32.3 0.000
Absent 
F.refractory shock Present 6.4 3.0, 13.3 0.02
Absent 
Peripheral temp Cold 8.5 2.7, 26.4 0.000
Warm
Peripheral pulse Absent 7.3 2.9, 18.2 0.000
Present 
unconcious Present 4.0 1.5, 10.8 0.03
Absent 
ALT > 3 times 2.7 1.0, 6.7 0.03
< 3 times
cholesterol <90.8 0.00
>90.8
CXR 
cardiomegaly
Present 26.8 6.9,104 0.000
Absent 
colloid Given 5.5 2.6,11.2 0.03
Not given
FFP/ prbc Given 2.85 1.4,5.6 0.02
Not given
Inotropes Given 8.2 4.6,16.2 0.01
Not given
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Table  12 Risk factor for death in DHF/DSS derived from multiple logistic 
regression analysis
variable OR 95% CI P value
fever > 5 days 7.9 1.2, 52.4 0.031
< 5 days
Convulsion present 21.8 2.3, 199.9 0.006
absent
Breathlessness present 11.1 1.73, 71.2 0.0111
absent
CXR 
cardiomegaly
present 75 5.6, 1006.04 0.0011
absent
Among the  various  factors  which were  analysed previously  ,  fever  >  5days 
OR(95%CI)  =  7.9(1.2,52.4),  Convulsion  OR(95%CI)  =  21.8(2.3,199.9), 
breathlessness OR(95%CI) = 11.1(1.7,71.2),  CXR cardiomegaly OR(95%CI) =
75(5.6,1006.4) are found to be the independent risk factor for death in DHF & 
DSS
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Discussion 
• In our study, infants less than 1 year is26.4%,were as  in the previous 
study 35% were infants ,  Age and gender have no value in predicting 
death in dengue hemorrhagic fever and dengue shock syndrome which is 
comparable to the study done previously5
• In our study, mortality in dengue hemorrhagic fever and dengue shock 
syndrome  is more in females (63.3%), so severity of disease is more in 
females  in  dengue  hemorrhagic  fever  and  dengue  shock  syndrome  , 
which is comparable to the study done previously Vinod H rategeri et al. 5
• In our study, lethargy (80%), convulsion (53.3%) in dengue hemorrhagic 
fever  and  dengue  shock  syndrome  are  associated  with  high  mortality 
which is comparable to study done previously patients who were referred 
late had profound shock and unconsciousness , expired within 24hours of 
admission Batra prerno et al 10. 
• In  present  study,  children  presented  late  to  the  hospital  with  fever 
(63.3%)in dengue hemorrhagic fever and dengue shock syndrome were 
associated  with  increase  mortality  which is  comparable  to  study done 
previously referred late expired within 24hours of admission Batra prerno 
et al 10. 
• In our study, among expired children in dengue hemorrhagic fever  and 
dengue  shock  syndrome   90%  were  presented  with  shock  which  is 
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comparable to the study done previously who  had profound shock  , 
expired within 24hours of admission  Banik et al Calcutta12. 
• In present study, fluid refractory shock in dengue hemorrhagic fever and 
dengue shock syndrome were  associated  with high mortality  which is 
comparable  to  the  others  study  done  previously  Patients  with  dengue 
shock syndrome are at high risk of mortality due to refractory shock and 
multiple organ failure Ranjit,el al17.
• In our study, cold periphery and absent peripheral pulses were present in 
30% of cases in dengue hemorrhagic fever and dengue shock syndrome 
associated with high mortality  which is  comparable  to the study done 
previously Banik et al Calcutta12.
• In our study, fever is present in 100% of patients with dengue which is 
comparable to the study done previously Ayyub m et al 15
• In our study ,mortality in  dengue hemorrhagic fever and   dengue shock 
syndrome in severely malnourished children is less than well nourished 
children  which  is  not  comparable  to  the  study  done  previously 
malnourished children had a higher risk of developing shock and high 
case fatality rate kalyana rooj et al 6
• In our study, platelet has no role in predicting the mortality in dengue 
haemorrhage fever and dengue shock syndrome  which is not comparable 
to the other study  done previously Chua mn et al9
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• In our study, Total cholesterol less than 90.8 mg is associated with high 
mortality  in  dengue  hemorrhagic  fever  and  dengue  shock  syndrome 
which is comparable to previous study Eric .C.M van grop et al 7.
• In  present  study,  Hematocrit  >37.5  was  not  associated  with  risk  for 
mortality  in  dengue  hemorrhagic  fever  and  dengue  shock  syndrome, 
which is not compared to the previous study in that hemoconcentration is 
associated  with  increase  risk  of  bleeding  and  subsequent  mortality 
Sivabalan et al chennai8.
• In our study, alanine transaminases level  more than 3 times normal is 
associated with increased risk for mortality in dengue hemorrhagic fever 
and dengue shock syndrome Which is comparable to the previously done 
studied  elevated   transaminases  level  increase  risk  of  bleeding  and 
subsequent mortality Sivabalan et al chennai8.
• In our study, requirement of colloids , blood products, and inotropes is  a 
risk  factor  for  mortality,  which  is  comparable  to  the  previous   study 
Aggressive shock management may decrease mortality rate Ranjit,el al17.
• In our study, cardiomegaly in chest x ray is 43.3% in expired children is associated 
with increased risk of mortality which is comparable with the previous study ECG 
and echocardiographic  abnormalities  are  common  during  the acute  phase  of 
dengue  haemorrhagic  fever. Cardiac involvement  in the pathogenesis  of the more 
severe  forms of dengue  k. Yusoff et al 23
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Summary and conclusion
In our study the following factors are found to be significantly associated with 
death in DHF/DSS 
1. Presented to hospital with fever > 5 days 
2. Convulsion
3. Breathlessness 
4. Cardiomegaly in Chest x ray  
Proper  history  ,good clinical  examination  and periodic  monitoring  the 
patients  would help us to identify patients at  risk for  bleeding and there by 
institute pompt treatment and reduce the mortality associate with DHF/DSS 
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ANNEXURE 1
Data Entry Form
Name                                 address
Age                                    IP number
Sex                                    date of admission 
Weight                               date of onset of illness
Height                                similar illness in family or locality
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Clinical features
Clinical feature Yes No Duration
fever
Headache
Myalgia 
Arthalgia 
Retro orbital pain
Abdomen pain
convulsion
Vomiting
Diarrhea
Skin bleeds (petechiae)
Mucosal bleeds(gum bleeds, 
epistaxis)
GI bleed(hematamysis, malena)
Other symptoms
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Signs 
Signs Yes No
Pallor
Icterus
Edema
Heart rate
Respiratory rate
CRT  >2 sec
Periphery cold
Peripheral pulse absent
Unconsciousness
Lymphadenopathy
Air entry equal in lungs 
Added sounds in lung
S3 gallop in CVS
Abdomen distension
Hepatomegaly 
Spleenomegaly
CNS  alert 
Verbal
Pain responsive
unresponsive
Lab investigation 
Haemoglobin
Total count – wbc
Differential count 
Platelet
Hematocrit
Electrolytes
Sugar
Urea
Creatinine
AST
ALT
Proteins
Total cholesterol
70
Chest xray
Ultra sonogram
Serology 
Treatment given 
Treatment yes No
Crystalloids
Colloids
Blood
Platelets
Inotropes
others
Outcome
Recovered
Death 
Fever in DHF & DSS in expired group 
fever <5 days; 36.70%
fever > 5 days; 63.30%
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convulsions in dengue hemorrhagic fever and dengue shock 
syndrome
expired recovered 
53.30%
26.30%
46.70%
73.70%
convulsions present convulsion absent Column1
Breathlessness in dengue hemorrhagic fever and dengue shock 
syndrome
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Cardiomegaly in DHF & DSS
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expired recovered
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